Fresenius Kabi's approved generic therapy addresses acute symptomatic hypocalcemia and targets a US market valued at nearly $71 million
The private funding rose 38% amid growing international collaborations and CDMO demand
Approval marks the second generic semaglutide clearance in Canada and strengthens OneSource’s position in complex injectable CDMO programs
Approval expands Lupin’s specialty portfolio in the US market for treatment of urea cycle disorders
Strong CDMO growth, improved product mix and operational leverage drive profitability expansion
CPHI India from 23–25 November 2026 at Yashobhoomi (India International Convention and Expo Centre), while PMEC India from 24–26 November 2026 at India Expo Mart
The medtech firm strengthens its full-stack remote cardiac monitoring platform, achieves 11x revenue growth, and advances its global expansion plans
Domestic sales increased 15.5%, supported by the relaunch of previously recalled products in the market
Collaboration to drive diagnostics exports, tap high-growth regional markets and build scalable commercialization platform
Inspection outcome reinforces company's compliance track record and strengthens its ability to serve regulated markets including the United States
Subscribe To Our Newsletter & Stay Updated
_256_275.jpeg)
